Retatrutide · 20 MG
$129.00
A single-compound 20 MG presentation of Retatrutide, identified on the established RTA artwork. Its documentation focuses on published clinical development and current investigational status.
12 in stock
A single-compound 20 MG presentation of Retatrutide, identified on the established RTA artwork. Its documentation focuses on published clinical development and current investigational status.
Understand the formulation
Retatrutide has been studied as an investigational triple-receptor agonist in clinical trials. Those studies do not make this 4eva Pep product an approved medicine or establish safety or efficacy for it.
Clinical research · phase 2 investigational trial
A randomized phase 2 trial evaluated retatrutide in adults with obesity and reported efficacy and safety findings under a controlled investigational protocol.
PubMed (PMID 37366315)
Review authoritative source : PubMed (PMID 37366315)Regulatory status · current FDA information
FDA states that retatrutide is not a component of an FDA-approved drug and has not been found safe and effective for any condition.
U.S. Food and Drug Administration
Review authoritative source : U.S. Food and Drug AdministrationResearch references describe the cited compounds or biological context; they do not establish a guaranteed outcome for this product or formulation.
